TAT Peptide Delivers Death-Signaling Protein FADD Into Cancer Cells to Trigger Apoptosis
A cell-penetrating TAT peptide delivered FADD protein directly into cancer cells, triggering apoptosis and simultaneously suppressing anti-apoptotic NF-κB signaling and inflammasome activation.
Quick Facts
What This Study Found
TAT-FADD entered cancer cells via caveolar endocytosis, assembled DISC to trigger apoptosis, suppressed NF-κB and downstream anti-apoptotic genes (Bcl2, cFLIPL, RIP1, cIAP2), and inhibited NLRP3 inflammasome priming and IL-1β secretion.
Key Numbers
TAT-FADD triggered DISC assembly; suppressed Bcl2, cFLIPL, RIP1, cIAP2; blocked NF-kB and NLRP3; reduced IL-1β
How They Did This
In vitro study: purified FADD protein chemically conjugated to TAT peptide. Tested internalization pathway, DISC assembly, apoptosis induction, NF-κB signaling, and NLRP3 inflammasome activity in cancer cell lines. Compared to conventional apoptosis inducers.
Why This Research Matters
Cancer cells survive by turning off their death signals. Directly delivering a death-signaling protein bypasses cancer's evasion mechanisms and simultaneously targets inflammation that promotes tumor growth.
The Bigger Picture
This represents a protein replacement therapy approach to cancer — instead of using small molecules to reactivate suppressed pathways, deliver the missing protein directly. The CPP delivery strategy could apply to other tumor suppressors.
What This Study Doesn't Tell Us
In vitro only — no animal or human data. TAT-FADD stability, immunogenicity, and tumor specificity in vivo are unknown. Manufacturing conjugated protein-peptide therapeutics at scale is challenging.
Questions This Raises
- ?Would TAT-FADD show anti-tumor activity in animal models without harming normal cells?
- ?Can TAT-FADD be targeted specifically to tumors to avoid systemic toxicity?
- ?How does TAT-FADD compare to gene therapy approaches for restoring FADD expression?
Trust & Context
- Key Stat:
- Multi-pathway attack TAT-FADD simultaneously triggered apoptosis, suppressed NF-κB survival signaling, and blocked inflammasome activation
- Evidence Grade:
- Preliminary — in vitro proof of concept demonstrating mechanism and efficacy in cell lines but no in vivo data.
- Study Age:
- Published in 2020; protein delivery via cell-penetrating peptides continues to advance in cancer research.
- Original Title:
- Cell-Penetrable Peptide-Conjugated FADD Induces Apoptosis and Regulates Inflammatory Signaling in Cancer Cells.
- Published In:
- International journal of molecular sciences, 21(18) (2020)
- Database ID:
- RPEP-05088
Evidence Hierarchy
Frequently Asked Questions
What is FADD and why do cancer cells suppress it?
FADD (Fas-associated death domain) is a protein that assembles the machinery for programmed cell death. Cancer cells often suppress FADD to avoid dying, allowing them to keep growing and resist treatment.
How does the TAT peptide get FADD inside cancer cells?
TAT is a cell-penetrating peptide derived from HIV that can cross cell membranes. When chemically attached to FADD protein, it carries the death-signaling protein through the cancer cell membrane via caveolar endocytosis.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05088APA
Ranjan, Kishu; Waghela, Bhargav N; Vaidya, Foram U; Pathak, Chandramani. (2020). Cell-Penetrable Peptide-Conjugated FADD Induces Apoptosis and Regulates Inflammatory Signaling in Cancer Cells.. International journal of molecular sciences, 21(18). https://doi.org/10.3390/ijms21186890
MLA
Ranjan, Kishu, et al. "Cell-Penetrable Peptide-Conjugated FADD Induces Apoptosis and Regulates Inflammatory Signaling in Cancer Cells.." International journal of molecular sciences, 2020. https://doi.org/10.3390/ijms21186890
RethinkPeptides
RethinkPeptides Research Database. "Cell-Penetrable Peptide-Conjugated FADD Induces Apoptosis an..." RPEP-05088. Retrieved from https://rethinkpeptides.com/research/ranjan-2020-cellpenetrable-peptideconjugated-fadd-induces
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.